GlassScriptPhysician profile
Hebatalla Osman
NPI 1093379828
$2,432.52
in general payments reported to CMS, 2019-2025
10 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,079 · 2021: $88.25 · 2022: $172 · 2023: $191 · 2024: $278 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,121.58 | 2020-2023 | Verquvo |
| Pfizer INC. | $391.78 | 2020-2023 | |
| Endotronix, INC. | $222.81 | 2025 | Cordella Pulomonary Artery Pressure Sensor, Cordella Pulmonary Artery Pressure Sensor |
| Cleerly, INC. | $150.30 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Amgen INC. | $148.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.87 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $120.74 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.56 | 2024 | Lifevest |
| Edwards Lifesciences Corporation | $42.51 | 2023-2024 | Sapien 3 Ultra Resilia |
| Abiomed | $38.46 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hebatalla Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.